Baptiste, P. J., Wong, A. Y. S., Schultze, A. ., Clase, C. M., Leyrat, C. ., Williamson, E. ., … Wing, K. . (2024). Cardiorenal effects of Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers in people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET). Am J Epidemiol. http://doi.org/10.1093/aje/kwae137
pharmacoepidemiology
Schultze, A. ., Martin, I. ., Messina, D. ., Bots, S. ., Belitser, S. ., Carreras-Martínez, J. ., … Douglas, I. . (2024). A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases. Vaccine, 42, 3039–3048. http://doi.org/10.1016/j.vaccine.2024.03.043
Eroglu, T. E., Coronel, R. ., & Souverein, P. C. (2024). Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study. Eur Heart J Cardiovasc Pharmacother. http://doi.org/10.1093/ehjcvp/pvae022
Shapiro, S. B., Yin, H. ., H. Y. Yu, O. ., & Azoulay, L. . (2024). Sodium-glucose cotransporter-2 inhibitors and the risk of lung cancer among patients with type 2 diabetes. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.16039
Pradhan, R. ., H. Y. Yu, O. ., Platt, R. W., & Azoulay, L. . (2023). Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study. BMJ Open Diabetes Res Care, 11. http://doi.org/10.1136/bmjdrc-2023-003550
Jödicke, A. M., Tan, E. H., Robinson, D. E., Delmestri, A. ., & Prieto-Alhambra, D. . (2023). Risk of adverse events following the initiation of antihypertensives in older people with complex health needs: a self-controlled case series in the United Kingdom. Age Ageing, 52. http://doi.org/10.1093/ageing/afad177
Abrahami, D. ., D’Andrea, E. ., Yin, H. ., Kim, S. C., Paik, J. M., Wexler, D. ., … Patorno, E. . (2023). Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. http://doi.org/10.1111/dom.15196
van Hulten, V. ., Driessen, J. H. M., Starup-Linde, J. K., Al-Mashhadi, Z. K., Viggers, R. ., Klungel, O. H., … van den Bergh, J. P. (2023). The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus. Diabetes Obes Metab. http://doi.org/10.1111/dom.15220
Ashworth, J. ., Bajpai, R. ., Muller, S. ., Bailey, J. ., Helliwell, T. ., Harrisson, S. A., … Mallen, C. D. (2023). Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study. The Lancet Regional Health - Europe, 27, 100579. http://doi.org/https://doi.org/10.1016/j.lanepe.2022.100579
Jani, M. ., Yimer, B. B., Selby, D. ., Lunt, M. ., Nenadic, G. ., & Dixon, W. G. (2023). "Take up to eight tablets per day": Incorporating free-text medication instructions into a transparent and reproducible process for preparing drug exposure data for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5595